CORCEPT THERAPEUTICS INC (CORT) Operating Margin
- Operating margin · 12 months: Value 0.77%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 0.77% | Operating income / revenue. Period ending 2026-06-30. $6.41M ÷ $830.81M × 100 ≈ 0.77% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 6.41M USD | Operating Income (Loss) |
| Revenue | 830.81M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 14.09M USD | Cost of Goods and Services Sold |
| Research and development | 253.86M USD | Research and Development Expense |
| Selling, general and administration | 556.47M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6.41M | $830.81M | $14.09M | $253.86M | $556.47M | 0.77% |
| 2026-03-31 | $-8.22M | $769.10M | $13.46M | $260.44M | $503.42M | -1.07% |
| 2025-12-31 | $44.80M | $761.41M | $12.98M | $254.91M | $448.73M | 5.88% |
| 2025-09-30 | $65.57M | $741.17M | $13.39M | $260.35M | $401.86M | 8.85% |
| 2025-06-30 | $101.95M | $716.08M | $11.66M | $250.84M | $351.63M | 14.24% |
| 2025-03-31 | $110.87M | $685.45M | $10.75M | $249.12M | $314.71M | 16.17% |
| 2024-12-31 | $136.95M | $675.04M | $10.88M | $246.89M | $280.32M | 20.29% |
| 2024-09-30 | $143.36M | $628.55M | $9.80M | $231.29M | $244.10M | 22.81% |
| 2024-06-30 | $127.94M | $569.61M | $8.58M | $217.48M | $215.62M | 22.46% |
| 2024-03-31 | $121.93M | $523.53M | $7.63M | $202.01M | $191.96M | 23.29% |
| 2023-12-31 | $107.28M | $482.38M | $6.48M | $184.35M | $184.26M | 22.24% |
| 2023-09-30 | $98.11M | $450.03M | $6.08M | $166.40M | $179.43M | 21.80% |
| 2023-06-30 | $98.87M | $428.15M | $5.78M | $154.17M | $169.33M | 23.09% |
| 2023-03-31 | $100.72M | $413.82M | $5.52M | $143.72M | $163.86M | 24.34% |
| 2022-12-31 | $112.63M | $401.86M | $5.38M | $130.99M | $152.85M | 28.03% |
| 2022-09-30 | $126.80M | $397.62M | $5.26M | $122.76M | $142.81M | 31.89% |
| 2022-06-30 | $131.10M | $392.03M | $5.20M | $117.56M | $138.18M | 33.44% |
| 2022-03-31 | $131.61M | $380.23M | $5.26M | $112.96M | $130.40M | 34.61% |
| 2021-12-31 | $124.48M | $365.98M | $5.28M | $113.86M | $122.36M | 34.01% |
| 2021-09-30 | $118.32M | $352.89M | $5.18M | $113.62M | $115.77M | 33.53% |
| 2021-06-30 | $106.81M | $343.09M | $5.12M | $119.40M | $111.76M | 31.13% |
| 2021-03-31 | $110.13M | $340.06M | $4.97M | $117.66M | $107.30M | 32.38% |
| 2020-12-31 | $128.20M | $353.87M | $5.58M | $114.76M | $105.33M | 36.23% |
| 2020-09-30 | $132.71M | $356.03M | $5.76M | $110.80M | $106.76M | 37.27% |
| 2020-06-30 | $140.99M | $351.21M | $6.00M | $99.74M | $104.49M | 40.14% |
| 2020-03-31 | $130.36M | $334.90M | $6.14M | $94.90M | $103.50M | 38.92% |
| 2019-12-31 | $111.61M | $306.49M | $5.50M | $89.02M | $100.36M | 36.41% |
| 2019-09-30 | $101.49M | $285.42M | $5.65M | $83.50M | $94.79M | 35.56% |
| 2019-06-30 | $91.46M | $268.36M | $5.50M | $79.55M | $91.85M | 34.08% |
| 2019-03-31 | $87.46M | $258.42M | $5.28M | $78.44M | $87.24M | 33.84% |
| 2018-12-31 | $89.50M | $251.25M | $5.21M | $75.25M | $81.29M | 35.62% |
| 2018-09-30 | $86.30M | (m) | (m) | $70.08M | $76.52M | (m) |
| 2018-06-30 | $76.95M | (m) | (m) | $62.92M | $71.69M | (m) |
| 2018-03-31 | $69.11M | (m) | (m) | $50.25M | $65.82M | (m) |
| 2017-12-31 | $52.85M | (m) | (m) | $40.38M | $62.42M | (m) |
| 2017-09-30 | $36.16M | (m) | (m) | $33.23M | $57.38M | (m) |
| 2017-06-30 | $25.61M | (m) | (m) | $28.59M | $51.84M | (m) |
| 2017-03-31 | $14.33M | (m) | (m) | $26.39M | $49.84M | (m) |
| 2016-12-31 | $10.18M | (m) | (m) | $23.84M | $45.24M | (m) |
| 2016-09-30 | $6.82M | (m) | (m) | $21.45M | $42.34M | (m) |
| 2016-06-30 | $3.85M | (m) | (m) | $18.01M | $40.70M | (m) |
| 2016-03-31 | $1.18M | (m) | (m) | $15.68M | $37.93M | (m) |
| 2015-12-31 | $-3.44M | (m) | (m) | $15.42M | $36.95M | (m) |
| 2015-09-30 | $-8.17M | (m) | (m) | $15.12M | $36.13M | (m) |
| 2015-06-30 | $-13.38M | (m) | (m) | $14.55M | $35.94M | (m) |
| 2015-03-31 | $-18.79M | (m) | (m) | $15.46M | $34.56M | (m) |
| 2014-12-31 | $-27.62M | (m) | (m) | $18.37M | $34.92M | (m) |
| 2014-09-30 | $-34.57M | (m) | (m) | $21.15M | $34.39M | (m) |
| 2014-06-30 | $-39.21M | (m) | (m) | $23.26M | $32.47M | (m) |
| 2014-03-31 | $-43.41M | (m) | (m) | $23.50M | $32.66M | (m) |
| 2013-12-31 | $-41.50M | (m) | (m) | $20.47M | $31.24M | (m) |
| 2013-09-30 | $-41.45M | (m) | (m) | $18.76M | $30.20M | (m) |
| 2013-06-30 | $-39.38M | (m) | (m) | $16.61M | $28.72M | (m) |
| 2013-03-31 | $-36.19M | (m) | (m) | $14.79M | $26.31M | (m) |
| 2012-12-31 | $-36.27M | (m) | (m) | $14.07M | $25.41M | (m) |
| 2012-09-30 | $-36.22M | (m) | (m) | $15.86M | (m) | (m) |
| 2012-06-30 | $-34.99M | (m) | (m) | $16.08M | (m) | (m) |
| 2012-03-31 | $-36.26M | (m) | (m) | $19.62M | (m) | (m) |
| 2011-12-31 | $-32.33M | (m) | (m) | $21.00M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-27.44M | (m) | (m) | $18.95M | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-20.25M | $29.00K | (m) | $14.40M | (m) | -69827.59% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |